Bronte Capital Management Pty Ltd. decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 4.2% during the first quarter, HoldingsChannel reports. The fund owned 37,245 shares of the biopharmaceutical company’s stock after selling 1,619 shares during the quarter. Alnylam Pharmaceuticals comprises about 1.3% of Bronte Capital Management Pty Ltd.’s investment portfolio, making the stock its 18th biggest holding. Bronte Capital Management Pty Ltd.’s holdings in Alnylam Pharmaceuticals were worth $12,323,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors have also recently made changes to their positions in the company. MV Capital Management Inc. purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $25,000. HM Payson & Co. purchased a new stake in Alnylam Pharmaceuticals during the 4th quarter worth about $27,000. Golden State Wealth Management LLC boosted its stake in Alnylam Pharmaceuticals by 100.0% in the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Alnylam Pharmaceuticals in the 3rd quarter worth about $29,000. Finally, Ameriflex Group Inc. purchased a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at about $32,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.
Analyst Ratings Changes
ALNY has been the topic of a number of recent analyst reports. Jefferies Financial Group reissued a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a report on Monday, March 16th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Royal Bank Of Canada decreased their target price on shares of Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating on the stock in a report on Friday, May 1st. HC Wainwright lowered their target price on shares of Alnylam Pharmaceuticals from $510.00 to $470.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Wells Fargo & Company raised their price target on shares of Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the company an “equal weight” rating in a report on Friday, May 1st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $461.39.
Trending Headlines about Alnylam Pharmaceuticals
Here are the key news stories impacting Alnylam Pharmaceuticals this week:
- Positive Sentiment: Wall Street analysts now see significant upside for Alnylam, with a recent report highlighting an average price target of $436, which suggests confidence in the stock’s longer-term growth potential.
- Positive Sentiment: HC Wainwright reiterated a Buy rating and a $470 price target, even while trimming some near-term earnings estimates, signaling that the firm still expects strong multi-year earnings growth for ALNY.
- Positive Sentiment: Komodo Health expanded its strategic partnership with Alnylam, extending work on Komodo’s Healthcare Map and Marmot analytics AI platform. The collaboration may support Alnylam’s data and AI-driven development efforts and reinforces the company’s commercial and operational execution. Article Title
- Neutral Sentiment: HC Wainwright lowered earnings estimates for Q2, Q3, Q4, FY2026, FY2027, FY2028 and FY2029, but also raised its FY2030 estimate. The revisions suggest some near-term caution, offset by optimism about Alnylam’s longer-term earnings trajectory.
Alnylam Pharmaceuticals Stock Performance
NASDAQ:ALNY opened at $312.78 on Friday. The company has a market capitalization of $41.76 billion, a price-to-earnings ratio of 85.46 and a beta of 0.27. The business has a 50 day moving average of $295.46 and a 200 day moving average of $328.42. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. Alnylam Pharmaceuticals, Inc. has a 1-year low of $273.11 and a 1-year high of $495.55.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. The business had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The business’s quarterly revenue was up 96.4% on a year-over-year basis. During the same period last year, the business earned ($0.44) earnings per share. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.
Insiders Place Their Bets
In related news, insider Melissa Mclaughlin sold 2,286 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the transaction, the insider owned 9,443 shares in the company, valued at $3,120,156.06. This trade represents a 19.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the completion of the sale, the director directly owned 1,582 shares of the company’s stock, valued at $473,302.76. This represents a 70.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is currently owned by corporate insiders.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Featured Articles
- Five stocks we like better than Alnylam Pharmaceuticals
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
